ARPA-H will host a Proposer’s Day on May 07, 2024. The
event will allow for both in-person and virtual participation and is intended
to facilitate teaming and foster a greater understanding of the PRINT Program. ARPA-H is soliciting
proposals to transform organ biofabrication by leveraging recent advances in 3D
bioprinting, cell manufacturing, biomaterials, modeling, and tissue
engineering. The platform will use patient-matched organ biofabrication to
restore normal human organ function for the kidney, heart, or liver.
Ultimately, ARPA-H intends to negotiate multiple Cooperative Agreements or
Other Transaction (OT) Agreements with proposers whose proposals are most
advantageous to the Government.
Proposals are expected to
use innovative approaches that include novel technology, enabling revolutionary
advances in medicine and healthcare. Specifically excluded are proposals that
represent an evolutionary or incremental advance in the current state of the
art, including clinical trials of an otherwise developed product. Additionally,
proposals directed towards policy changes, traditional education and training,
or center coordination, formation, or development, and construction of physical
infrastructure are outside the scope of the ARPA-H mission.
PRINT program will address
these limitations by:
- Selecting patient cell
sources and developing effective protocols to differentiate/expand all necessary
organ specific cell types while maintaining immunocompetence.
Developing large scale
Good Laboratory Practice (GLP)/GMP manufacturing processes, cell biobank, and
effective storage and cell transport conditions.
Developing a library of
natural and synthetic bioinks for structural integrity while exhibiting native tissue
biomechanics, effective vascularization at the time of print, self-assembly of
tissue units, and unique native tissue environments.
Building high speed and
precision bioprinting software and hardware.
Developing a bioreactor
system that will enable active perfusions at the time and point, post print maturation,
and maintain viability up to transplantation.
Down-selecting to the most
promising teams for functional and structural evaluation in a large animal
model.
|